Aurisco Pharmaceutical Co. Ltd. Class A

Aurisco Pharmaceutical Co. Ltd. Class A

SSSE:605116
16.80
CNY
-0.49
(-2.83%)
0.77EPS
25.64P/E
8.15BMarket Cap
Apr 22Next Earn

Total Valuation

CNY

As of September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A carries a market capitalization of 8.15B, placing it among publicly traded companies globally. Its enterprise value stands at 8.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.15B
Enterprise Value8.52B

Important Dates

Aurisco Pharmaceutical Co. Ltd. Class A's next confirmed earnings release is scheduled for April 22, 2027.

Earnings Date4/22/2027

Share Statistics

As of September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A has 406.18M shares outstanding.

Shares Outstanding406.18M

Valuation Ratios

As of September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 25.64. The price-to-sales ratio is 4.85, and the price-to-book ratio stands at 2.98.

PE Ratio25.64
PS Ratio4.85
PB Ratio2.98
P/TBV Ratio3.16

Enterprise Valuation

As of September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A trades at an EV/EBITDA multiple of 23.01 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.01 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 8.52B versus a market cap of 8.15B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.09
EV / EBITDA23.01
EV / EBIT23.01

Financial Position

As of September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A maintains a current ratio of 3.67, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 35.56, indicating elevated leverage, while an interest coverage ratio of 10.57 demonstrates strong ability to service its debt obligations.

Current Ratio3.67
Quick Ratio1.26
Debt / Equity35.56
Debt / EBITDA2.63
Interest Coverage10.57

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A posted a return on equity (ROE) of 12.25, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.90 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.75, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.73, useful for judging operating efficiency across full business cycles. The company generates approximately 826,458.12 in revenue per employee across its workforce of 2,026.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.14 indicates how many times Aurisco Pharmaceutical Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)12.25
Return on Assets (ROA)7.75
Return on Invested Capital (ROIC)8.90
Return on Capital Employed (ROCE)9.73
Revenue Per Employee826,458.12
Employee Count2,026.00
Inventory Turnover1.14

Taxes

CNY

Over the twelve months ended September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A recorded 52.46M in income tax expense. That works out to an effective tax rate of 14.22, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 368.99M, leaving 316.53M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax52.46M
Effective Tax Rate14.22

Stock Price Statistics

CNY

As of the close on November 17, 2026, Aurisco Pharmaceutical Co. Ltd. Class A's stock has declined approximately 27.43% over the past 52 weeks. The 50-day moving average sits at 18.93, while the 200-day moving average is 22.17.

52-Week Price Change-27.43%
50-Day Moving Average18.93
200-Day Moving Average22.17

Income Statement

CNY

Over the twelve months ended September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A generated 1.67B in revenue and converted that into 316.53M in net income, yielding earnings per share of 0.77. EBITDA reached 370.44M, while operating income came in at 447.42M.

Revenue1.67B
Gross Profit910.85M
Operating Income447.42M
Pretax Income368.99M
Net Income316.53M
EBITDA370.44M
EBIT370.44M
Earnings Per Share (EPS)0.77

Balance Sheet

CNY

As of September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A holds 601.36M in cash and equivalents against 973.38M in total debt, resulting in a net debt position of 493.21M. Total book value stands at 2.74B, with working capital of 1.27B providing operational flexibility.

Cash & Cash Equivalents601.36M
Total Debt973.38M
Net Debt493.21M
Equity (Book Value)2.74B
Book Value Per Share6.74
Working Capital1.27B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-366.73M

Margins

Over the twelve months ended September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A posted a gross margin of 54.40, reflecting its pricing power and cost economics. The operating margin of 26.72 and net profit margin of 18.90 provide insight into operational efficiency.

Gross Margin54.40
Operating Margin26.72
Pretax Margin22.04
Profit Margin18.90
EBITDA Margin22.12

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A paid dividends of 0.35 per share. The dividend payout ratio of 45.18 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.43, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Aurisco Pharmaceutical Co. Ltd. Class A shareholders.

Dividend Per Share0.35
Payout Ratio45.18
Shareholder Yield2.43

Scores

As of September 30, 2026, Aurisco Pharmaceutical Co. Ltd. Class A has an Altman Z-Score of 4.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.86